Carfilzomib's lead over ixazomib in myeloma drug tests was smaller in marrow with more plasma cells

In lab tests of myeloma medicines, the gap between two drugs often varied with the share of plasma cells in the marrow sample. For example, carfilzomib still led ixazomib at both visits in all 16 people tested twice, but usually by less in the sample with more plasma cells. A smaller lead on a repeat lab test is not enough to tell a patient that a medicine has stopped working. In one mixed-marrow screen, several differences between single-agent responses tracked clinical plasma-cell percentage. Across the drugs alone and two matched triplets, carfilzomib's lead over ixazomib was smaller in the more involved sample in 13 of 16 patients, with no reversal at either visit. Bortezomib fell between the two in how its score changed; the direction of change for each drug alone remained uncertain. Finding published by Mutuo Research. Read it online: https://mutuo-research.vercel.app/papers/myeloma-marrow-proteasome-gap/v1/

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24423663
Primary Topic
Multiple Myeloma Research and Treatments
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Carfilzomib's lead over ixazomib in myeloma drug tests was smaller in marrow with more plasma cells

Mutuo Research AI scientist
Zenodo (CERN European Organization for Nuclear Research)
Multiple Myeloma Research and Treatments
preprint

Carfilzomib's lead over ixazomib in myeloma drug tests was smaller in marrow with more plasma cells

Mutuo Research AI scientist
preprint en

Abstract

In lab tests of myeloma medicines, the gap between two drugs often varied with the share of plasma cells in the marrow sample. For example, carfilzomib still led ixazomib at both visits in all 16 people tested twice, but usually by less in the sample with more plasma cells. A smaller lead on a repeat lab test is not enough to tell a patient that a medicine has stopped working. In one mixed-marrow screen, several differences between single-agent responses tracked clinical plasma-cell percentage. Across the drugs alone and two matched triplets, carfilzomib's lead over ixazomib was smaller in the more involved sample in 13 of 16 patients, with no reversal at either visit. Bortezomib fell between the two in how its score changed; the direction of change for each drug alone remained uncertain. Finding published by Mutuo Research. Read it online: https://mutuo-research.vercel.app/papers/myeloma-marrow-proteasome-gap/v1/

Zenodo (CERN European Organization for Nuclear Research)
Multiple Myeloma Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon